{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:54:06Z","timestamp":1762005246090,"version":"build-2065373602"},"reference-count":40,"publisher":"Knowledge E DMCC","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["knepublishing.com"],"crossmark-restriction":true},"short-container-title":["IJRM"],"abstract":"<jats:p>Background: Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.\r\nObjective: To evaluate pain intensity reduction as the primary outcome and assess side effects and quality of life as secondary outcomes through an updated meta-analysis.\r\nMaterials and Methods: A systematic search was conducted in Cochrane, Scopus, and PubMed\/Medline. Study quality was assessed using the Cochrane risk of bias in non-randomized studies of interventions tool. The pooled standard mean difference and p-value were calculated using a random-effects model (DerSimonian-Laird method), and the inconsistency index was applied to evaluate heterogeneity.\r\nResults: 7 randomized controlled trials were included. Gonadotropin-releasing hormone antagonists significantly reduced dysmenorrhea, dyspareunia, and non-menstrual chronic pelvic pain when measured with the verbal and numeric rating scales, but not with the modified Biberoglu and Behrman score. Secondary outcomes showed significant improvements in health status (endometriosis health profile and patient global impression of change). However, treatment was associated with increased hot flushes (3.61-fold higher), an 8.96% increase in low-density lipoprotein after 6 months, and a rise in high-density lipoprotein compared with placebo. Bone mineral density in the spine was significantly lower in the treatment group (p &lt; 0.001).\r\nConclusion: This meta-analysis provides updated evidence on Elagolix, Linzagolix, and Relugolix, confirming their effectiveness in managing endometriosis-associated pain, while highlighting important considerations regarding metabolic and bone health.<\/jats:p>","DOI":"10.18502\/ijrm.v23i9.20156","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:21:56Z","timestamp":1762003316000},"page":"671-688","update-policy":"https:\/\/doi.org\/10.18502\/knecrossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials"],"prefix":"10.18502","volume":"23","author":[{"given":"Dian","family":"Tjahyadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Sudono","family":"Riyadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annisa Dewi","family":"Nugrahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulyanusa Amarullah","family":"Ritonga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Rachmawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tita Husnitawati","family":"Madjid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7770","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"307781","unstructured":"[1] Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: Endometriosis. Hum Reprod Open 2022: hoac009."},{"key":"307782","doi-asserted-by":"crossref","unstructured":"[2] Kennedy S, Bergqvist A, Chapron C, D\u2019Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698\u20132704.","DOI":"10.1093\/humrep\/dei135"},{"key":"307783","doi-asserted-by":"crossref","unstructured":"[3] Margueritte F, Fritel X, Zins M, Goldberg M, Panjo H, Fauconnier A, et al. The underestimated prevalence of neglected chronic pelvic pain in women: A nationwide cross-sectional study in France. J Clin Med 2021; 10: 2481.","DOI":"10.3390\/jcm10112481"},{"key":"307784","doi-asserted-by":"crossref","unstructured":"[4] Cozzolino M, Coccia ME, Lazzeri G, Basile F, Troiano G. Variables associated with endometriosis-related pain: A pilot study using a visual analogue scale. Rev Bras Ginecol Obstet 2019; 41: 170\u2013175.","DOI":"10.1055\/s-0039-1679879"},{"key":"307785","doi-asserted-by":"crossref","unstructured":"[5] Howard FM. Chronic pelvic pain. Obstet Gynecol 2003; 101: 594\u2013611.","DOI":"10.1016\/S0029-7844(02)02723-0"},{"key":"307786","doi-asserted-by":"crossref","unstructured":"[6] Sekiguchi H, Ii M, Jujo K, Thorne T, Ito A, Klyachko E, et al. Estradiol promotes neural stem cell differentiation into endothelial lineage and angiogenesis in injured peripheral nerve. Angiogenesis 2013; 16: 45\u201358.","DOI":"10.1007\/s10456-012-9298-5"},{"key":"307787","doi-asserted-by":"crossref","unstructured":"[7] Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: How to choose a scale? Hum Reprod Update 2015; 21: 136\u2013152.","DOI":"10.1093\/humupd\/dmu046"},{"key":"307788","doi-asserted-by":"crossref","unstructured":"[8] Carr B, Dmowski WP, O\u2019Brien Ch, Jiang P, Burke J, Jimene R, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density. Reprod Sci 2014; 21: 1341\u20131351.","DOI":"10.1177\/1933719114549848"},{"key":"307789","doi-asserted-by":"crossref","unstructured":"[9] Diamond MP, Carr B, Dmowski WP, Koltun W, O\u2019brien Ch, Jiang P, et al. Elagolix treatment for endometriosisassociated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014; 21: 363\u2013371.","DOI":"10.1177\/1933719113497292"},{"key":"307790","doi-asserted-by":"crossref","unstructured":"[10] Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: A randomized clinical trial. Fertil Steril 2020; 114: 44\u201355.","DOI":"10.1016\/j.fertnstert.2020.02.114"},{"key":"307791","doi-asserted-by":"crossref","unstructured":"[11] Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, et al. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: A prospective, randomized, double-blind, phase 3 study (EDELWEISS 3). Hum Reprod 2024; 39: 1208\u20131221.","DOI":"10.1093\/humrep\/deae076"},{"key":"307792","doi-asserted-by":"crossref","unstructured":"[12] Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: Two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet 2022; 399: 2267\u20132279.","DOI":"10.1016\/S0140-6736(22)00622-5"},{"key":"307793","doi-asserted-by":"crossref","unstructured":"[13] Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: A randomized, double-blind, placebo-controlled study. Fertil Steril 2021; 115: 397\u2013405.","DOI":"10.1016\/j.fertnstert.2020.07.055"},{"key":"307794","doi-asserted-by":"crossref","unstructured":"[14] Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 2017; 377: 28\u201340.","DOI":"10.1056\/NEJMoa1700089"},{"key":"307795","doi-asserted-by":"crossref","unstructured":"[15] Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of Elagolix: An oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet 2020; 59: 297\u2013309.","DOI":"10.1007\/s40262-019-00840-7"},{"key":"307796","doi-asserted-by":"crossref","unstructured":"[16] Tezuka M, Tamai Y, Kuramochi Y, Kobayashi K, Fushimi N, Kiguchi S. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors. Clin Exp Pharmacol Physiol 2022; 49: 1082\u20131093.","DOI":"10.1111\/1440-1681.13688"},{"key":"307797","doi-asserted-by":"crossref","unstructured":"[17] Syed YY. Relugolix\/Estradiol\/Norethisterone (Norethindrone) acetate: A review in symptomatic uterine fibroids. Drugs 2022; 82: 1549\u20131556.","DOI":"10.1007\/s40265-022-01790-4"},{"key":"307798","doi-asserted-by":"crossref","unstructured":"[18] Yan H, Shi J, Li X, Dai Y, Wu Y, Zhang J, et al. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: A systematic review and network meta-analysis. Fertil Steril 2022; 118: 1102\u20131116.","DOI":"10.1016\/j.fertnstert.2022.08.856"},{"key":"307799","doi-asserted-by":"crossref","unstructured":"[19] Xin L, Ma Y, Ye M, Chen L, Liu F, Hou Q. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: A systematic review and network meta-analysis. Arch Gynecol Obstet 2023; 308: 1047\u20131056.","DOI":"10.1007\/s00404-022-06862-0"},{"key":"307800","doi-asserted-by":"crossref","unstructured":"[20] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: 71.","DOI":"10.1136\/bmj.n71"},{"key":"307801","doi-asserted-by":"crossref","unstructured":"[21] Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557\u2013560.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"307802","doi-asserted-by":"crossref","unstructured":"[22] Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ 2019; 364: k4597.","DOI":"10.1136\/bmj.k4597"},{"key":"307803","doi-asserted-by":"crossref","unstructured":"[23] Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991\u2013996.","DOI":"10.1016\/j.jclinepi.2007.11.010"},{"key":"307804","doi-asserted-by":"crossref","unstructured":"[24] Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: Pathogenesis and treatment. Nat Rev Endocrinol 2014; 10: 261\u2013275.","DOI":"10.1038\/nrendo.2013.255"},{"key":"307805","doi-asserted-by":"crossref","unstructured":"[25] The Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: A committee opinion. Fertil Steril 2014; 10: 927\u2013935.","DOI":"10.1016\/j.fertnstert.2014.02.012"},{"key":"307806","doi-asserted-by":"crossref","unstructured":"[26] Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 4: CD001750.","DOI":"10.1002\/14651858.CD001750.pub4"},{"key":"307807","doi-asserted-by":"crossref","unstructured":"[27] Howard FM. Endometriosis and mechanisms of pelvic pain. J Minim Invasive Gyecol 2009; 16: 540\u2013550.","DOI":"10.1016\/j.jmig.2009.06.017"},{"key":"307808","doi-asserted-by":"crossref","unstructured":"[28] Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: Translational evidence of the relationship and implications. Hum Reprod Update 2011; 17: 327\u2013346.","DOI":"10.1093\/humupd\/dmq050"},{"key":"307809","doi-asserted-by":"crossref","unstructured":"[29] Reed SD. Dyspareunia-where and why the pain? Menopause 2022; 29: 639\u2013641.","DOI":"10.1097\/GME.0000000000002001"},{"key":"307810","unstructured":"[30] Feingold KR. The effect of endocrine disorders on lipids and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000."},{"key":"307811","doi-asserted-by":"crossref","unstructured":"[31] Miku\u0161 M, Matak L, Vuji\u0107 G, \u0160kegro B, \u0160kegro I, Augustin G, et al. The short form endometriosis health profile questionnaire (EHP-5): Psychometric validity assessment of a Croatian version. Arch Gynecol Obstet 2023; 307: 87\u201392.","DOI":"10.1007\/s00404-022-06691-1"},{"key":"307812","doi-asserted-by":"crossref","unstructured":"[32] Abrao MS, Surrey E, Gordon K, Snabes MC, Wang H, Ijacu H, et al. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients. BMC Womens Health 2021; 21: 246.","DOI":"10.1186\/s12905-021-01385-3"},{"key":"307813","doi-asserted-by":"crossref","unstructured":"[33] Scott W, McCracken LM. Patients\u2019 impression of change following treatment for chronic pain: Global, specific, a single dimension, or many? J Pain 2015; 16: 518\u2013526.","DOI":"10.1016\/j.jpain.2015.02.007"},{"key":"307814","doi-asserted-by":"crossref","unstructured":"[34] Hansen KE, Lambek R, R\u00f8ssaak K, Egekvist AG, Marschall H, Forman A, et al. Health-related quality of life in women with endometriosis: Psychometric validation of the endometriosis health profile 30 questionnaire using confirmatory factor analysis. Hum Reprod Open 2021; 2022: hoab042.","DOI":"10.1093\/hropen\/hoab042"},{"key":"307815","doi-asserted-by":"crossref","unstructured":"[35] Grundstr\u00f6m H, Rauden A, Wikman P, Olovsson M. Psychometric evaluation of the Swedish version of the 30-item endometriosis health profile (EHP-30). BMC Womens Health 2020; 20: 204.","DOI":"10.1186\/s12905-020-01067-6"},{"key":"307816","doi-asserted-by":"crossref","unstructured":"[36] Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the generation of hot flushes. Cell Rep 2018; 24: 271\u2013277.","DOI":"10.1016\/j.celrep.2018.06.037"},{"key":"307817","doi-asserted-by":"crossref","unstructured":"[37] Anastasilakis AD, Polyzos SA, Vorkas PA, Gkiomisi A, Yavropoulou MP, Rauner M, et al. Lipid profile after pharmacologic discontinuation and restoration of menstruation in women with endometriosis: A 12-month observational prospective study. J Clin Med 2023; 12: 5430.","DOI":"10.3390\/jcm12165430"},{"key":"307818","doi-asserted-by":"crossref","unstructured":"[38] Niaz R, Saeed M, Khan H, Ali MA, Irshad A, Faiz M, et al. Efficacy and safety of oral GnRh antagonists in patients with uterine fibroids: A systematic review. J Obstet Gynaecol Can 2022; 44: 1279\u20131288.","DOI":"10.1016\/j.jogc.2022.10.012"},{"key":"307819","doi-asserted-by":"crossref","unstructured":"[39] Sauerbrun-Cutler MT, Alvero R. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. Fertil Steril 2019; 112: 799\u2013803.","DOI":"10.1016\/j.fertnstert.2019.09.037"},{"key":"307820","doi-asserted-by":"crossref","unstructured":"[40] Hsu SH, Chen LR, Chen KH. Primary osteoporosis induced by androgen and estrogen deficiency: The molecular and cellular perspective on pathophysiological mechanisms and treatments. Int J Mol Sci 2024; 25: 12139.","DOI":"10.3390\/ijms252212139"}],"container-title":["International Journal of Reproductive BioMedicine (IJRM)"],"original-title":[],"link":[{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/download\/20156\/30776","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/download\/20156\/30776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:43:11Z","timestamp":1762004591000},"score":1,"resource":{"primary":{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/view\/20156"},"secondary":[{"URL":"http:\/\/ijrm.ir\/article-1-3513-en.html","label":"UNIVERSITY"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.18502\/ijrm.v23i9.20156","relation":{},"ISSN":["2476-3772","2476-4108"],"issn-type":[{"type":"electronic","value":"2476-3772"},{"type":"print","value":"2476-4108"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}